AIM： To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension （OHT） patients with inadequate intraocular pressure （lOP） on current therapy. METHODS： Pre- and pos...AIM： To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension （OHT） patients with inadequate intraocular pressure （lOP） on current therapy. METHODS： Pre- and post-switch lOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in lOP post-pre switch was analyzed using a 2-sided Student＇s paired t-test at the 5% significance level. RESULTS： There was a statistically significant mean reduction in lOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment （P〈0.001）. Subgroup analysis also demonstrated a statistically significant mean reduction in lOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy （P〈0.001）. CONCLUSION： This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.展开更多
文摘AIM： To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension （OHT） patients with inadequate intraocular pressure （lOP） on current therapy. METHODS： Pre- and post-switch lOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in lOP post-pre switch was analyzed using a 2-sided Student＇s paired t-test at the 5% significance level. RESULTS： There was a statistically significant mean reduction in lOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment （P〈0.001）. Subgroup analysis also demonstrated a statistically significant mean reduction in lOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy （P〈0.001）. CONCLUSION： This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.
